The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

@article{Ochaion2008TheAA,
  title={The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.},
  author={Avivit Ochaion and Sara Bar-Yehuda and Shira Cohen and Howard Amital and Kenneth A. Jacobson and Bhalchandra Joshi and Zhi Gao and Faina Barer and Renana Patoka and Luis J Del Valle and Georginia Perez-Liz and Pnina Fishman},
  journal={Biochemical pharmacology},
  year={2008},
  volume={76 4},
  pages={482-94}
}
The A(3) adenosine receptor (A(3)AR) is over-expressed in inflammatory cells and was defined as a target to combat inflammation. Synthetic agonists to this receptor, such as IB-MECA and Cl-IB-MECA, exert an anti-inflammatory effect in experimental animal models of adjuvant- and collagen-induced arthritis. In this study we present a novel A(3)AR agonist… CONTINUE READING